Strange: Bullish RARE Analysts Actually See -7.88% Downside
July 02, 2018 at 09:58 AM EDT
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Ultragenyx Pharmaceutical Inc (RARE). The average 12-month price target for RARE averaging the work of 16 analysts reveals an average price target of $70.81/share..
